Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Thiazide-Class Diuretics

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.

The French journal of urology·2024

Same author

Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience.

The French journal of urology·2023

Same author

[Bladder augmentation in the era of botulinum toxin: Indications and results].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

Same author

Saline bladder infusion vs standard catheter removal in patients with acute urinary retention related to benign prostatic hyperplasia: The BLAPERF Study.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

Same author

[Evaluation of the results and feasibility of vibration, diuresis and inversion therapy in the treatment of upper urinary tract stones].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Same author

A multi-institutional experience of Micro-percutaneous Nephrolithotomy (MicroPERC) for renal stones: Results and feasibility of day case surgery.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Same journal

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

Same journal

[Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

Same journal

[Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

Same journal

[Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

Same journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

Same journal

[Male contraception].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

[PSA and spironolactone].

S Rybikowski¹, C Maurin, J Deturmeny

¹Service d'urologie, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France. stanryb@free.fr

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie

|February 10, 2010

Summary

This summary is machine-generated.

Spironolactone, a potassium-sparing diuretic, may help manage prostate cancer progression. In a case study, spironolactone treatment normalized prostate-specific antigen (PSA) levels in a patient with recurrent prostate cancer.

Related Experiment Videos

Last Updated: Jun 16, 2026

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Area of Science:

Endocrinology
Oncology
Nephrology

Background:

Spironolactone is a potassium-sparing diuretic with antiandrogenic properties, primarily used for conditions like hirsutism.
Its role in managing prostate cancer, particularly in patients with ascites, remains less understood.
Prostate cancer recurrence after initial treatment poses a significant clinical challenge.

Observation:

A 72-year-old male patient with recurrent prostate cancer, previously treated with hormonal radiotherapy, developed ascites.
Spironolactone was administered to manage the ascites.
The patient exhibited a normalization of prostate-specific antigen (PSA) levels following the initiation of spironolactone therapy.

Findings:

The patient experienced a normalization of PSA levels after starting spironolactone for ascites.
Nine months post-treatment initiation, there were no clinical or biological indicators of prostate cancer progression.
This suggests a potential disease-modulating effect of spironolactone in recurrent prostate cancer.

Implications:

This case highlights a potential novel application for spironolactone in managing recurrent prostate cancer.
Further research is warranted to explore the antiandrogenic and diuretic effects of spironolactone in prostate cancer patients.
Spironolactone could represent a therapeutic option for managing ascites and potentially influencing disease progression in select prostate cancer cases.